Product Dev Landscape
Overview
Our drug candidates, ‘1805 and ‘1104, are in development to achieve superior long-term disease remission with less frequent dosing, as compared to current therapies, without suppressing the immune system.
‘1805 has demonstrated remission of disease in rheumatoid arthritis up to 12 weeks from a single dose in a Phase 2 study. ‘1104 has been shown to be safe and well tolerated in two clinical studies as well as proving to be a key regulatory of an inflammatory protein in allergic disease. In addition, both have demonstrated strong efficacy and safety in many preclinical studies to date.
